Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 21;20(5):e0324529.
doi: 10.1371/journal.pone.0324529. eCollection 2025.

Urinary apolipoprotein A4 as a biomarker for renal allograft injury in kidney transplant recipients

Affiliations

Urinary apolipoprotein A4 as a biomarker for renal allograft injury in kidney transplant recipients

Youn Kyung Kee et al. PLoS One. .

Abstract

Chronic renal allograft injury (CRAI) is a major cause of allograft loss in kidney transplant recipients (KTRs). The aim of this study was to evaluate the associations of urinary apolipoprotein A4 (ApoA-IV) levels with renal function and rapid renal function decline in KTRs. This study included 50 KTRs. Proteomic analysis via liquid chromatography‒mass spectrometry and tandem mass spectrometry (LC-MS/MS) was performed to identify potential urinary biomarkers. The SWATH (sequential window acquisition of all theoretical mass spectra) method was used for protein quantification. Urinary ApoA-IV levels were validated by enzyme-linked immunosorbent assay (ELISA). Rapid renal function decline was defined as an estimated glomerular filtration rate (GFR) decrease of >3 mL/min/1.73 m2 per year or initiation of dialysis. The log-transformed urinary ApoA-IV levels measured by ELISA had a significantly inverse correlation with the estimated GFR (r = -0.72, P < 0.001). Moreover, urinary ApoA-IV levels were higher in patients with rapid renal function decline than in those with stable renal function (215.4 ± 181.8 μg/mL vs. 42.5 ± 72.4 μg/mL, P = 0.001). Univariate logistic regression analysis revealed that log-transformed urinary ApoA-IV levels were significantly associated with rapid renal function decline (odds ratio [OR] 6.70, 95% confidence interval [CI] 2.56-22.83; P < 0.001). Multiple logistic regression showed urinary ApoA-IV levels remained a significant risk factor for rapid renal function decline (OR 4.10, 95% CI 1.10-19.55; P = 0.047). ROC curve analysis revealed the area under the curve (AUC) of 0.834 (95% CI 0.722-0.945, P < 0.001) for urinary ApoA-IV levels in predicting rapid renal function decline. Our results suggest that urinary ApoA-IV levels might be a potential biomarker for renal allograft function and could be used as a predictor for rapid renal function decline in KTRs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. The correlation between urinary apolipoprotein A4 (ApoA-IV) levels and renal allograft function according to estimated glomerular filtration rate in kidney transplant recipients.
The log-transformed urinary ApoA-IV levels measured by ELISA had significantly inverse correlation with the estimated glomerular filtration rate in kidney transplant recipients.
Fig 2
Fig 2. Association between urinary apolipoprotein A4 (ApoA-IV) levels and rapid renal function decline in kidney transplant recipients.
(A) Comparison of urinary ApoA-IV levels between the rapid renal function decline group and the stable renal function group in kidney transplant recipients. Boxplot showing significantly higher urinary ApoA-IV levels in patients with rapid renal function decline. (B) ROC curve of ApoA-IV for rapid renal function decline in kidney transplant recipients. ROC curve demonstrating the predictive value of urinary ApoA-IV for rapid renal function decline (AUC = 0.834). Urinary ApoA-IV levels above 102.16 μg/mL were associated with increased risk of rapid renal function decline.

Similar articles

References

    1. Riella LV, Djamali A, Pascual J. Chronic allograft injury: Mechanisms and potential treatment targets. Transplant Rev (Orlando). 2017;31(1):1–9. doi: 10.1016/j.trre.2016.10.005 . - DOI - PubMed
    1. Pascual J, Pérez-Sáez MJ, Mir M, Crespo M. Chronic renal allograft injury: early detection, accurate diagnosis and management. Transplant Rev (Orlando). 2012;26(4):280–90. doi: 10.1016/j.trre.2012.07.002 - DOI - PubMed
    1. Ganji MR, Harririan A. Chronic allograft dysfunction: major contributing factors. Iran J Kidney Dis. 2012;6(2):88–93. - PubMed
    1. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al.. Banff ’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN’). Am J Transplant. 2007;7(3):518–26. doi: 10.1111/j.1600-6143.2006.01688.x - DOI - PubMed
    1. Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, et al.. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol. 2002;13(2):461–9. doi: 10.1681/ASN.V132461 - DOI - PubMed